Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

The impact of extrahepatic disease among patients undergoing liver-directed therapy for neuroendocrine liver metastasis.

The impact of extrahepatic disease among patients undergoing liver-directed therapy for neuroendocrine liver metastasis. Journal of surgical oncology Ejaz, A., Reames, B. N., Maithel, S., Poultsides, G. A., Bauer, T. W., Fields, R. C., Weiss, M., Marques, H. P., Aldrighetti, L., Pawlik, T. M. 2017; 116 (7): 841-847

Abstract

Management of neuroendocrine liver metastasis (NELM) in the presence of extrahepatic disease (EHD) is controversial. We sought to examine outcomes of patients undergoing liver-directed therapy (resection, ablation, or both) for NELM in the presence of EHD using a large international cohort of patients.612 patients who underwent liver-directed therapy were identified from eight institutions. Postoperative outcomes, as well as and overall (OS) were compared among patients with and without EHD.Most primary tumors were located in the pancreas (N?=?254;41.8%) or the small bowel (N?=?188;30.9%). Patients underwent surgery alone (N?=?471;77.0%), ablation alone (N?=?15;2.5%), or a combined approach (N?=?126;20.6%). Patients with EHD had more high-grade tumors (EHD: 44.4% vs no EHD: 16.1%; P?

View details for DOI 10.1002/jso.24727

View details for PubMedID 28650564